Cost-effectiveness of direct-acting antiviral treatment in hepatitis c-infected liver transplant candidates with compensated cirrhosis and hepatocellular carcinoma

Transplantation

Volumn 101, Issue 5, 2017, Pages 1001-1008

  Salazar, James ^a   Saxena, Varun ^a   Kahn, James G ^b   Roberts, John P ^a   Mehta, Neil ^a   Volk, Michael ^c   Lai, Jennifer C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOMA LINDA UNIVERSITY HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR PLUS SOFOSBUVIR; RIBAVIRIN; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE; LEDIPASVIR, SOFOSBUVIR DRUG COMBINATION; URIDINE PHOSPHATE;

ANTIVIRAL THERAPY; COMPENSATED LIVER CIRRHOSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; GEOGRAPHY; HEPATIC AVAILABILITY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; ORGAN DONOR; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; REVIEW; SOCIAL ASPECT; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; COST BENEFIT ANALYSIS; DRUG ADMINISTRATION; ECONOMIC MODEL; ECONOMICS; HEPATITIS C, CHRONIC; LIVER CIRRHOSIS; LIVER TUMOR; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUORENES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MIDDLE AGED; MODELS, ECONOMIC; POSTOPERATIVE CARE; PREOPERATIVE CARE; QUALITY-ADJUSTED LIFE YEARS; RIBAVIRIN; UNITED STATES; URIDINE MONOPHOSPHATE;

EID: 85002213659     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000001605     Document Type: Review

References (33)

1. Marroquin CE, Marino G, Kuo PC, et al. Transplantation of hepatitis C-positive livers in hepatitis C-positive patients is equivalent to transplanting hepatitis C-negative livers. Liver Transpl. 2001;7:762-768.
2. Ricchiuti A, Brunati A, Mirabella S, et al. Use of hepatitis C virus-positive grafts in liver transplantation: a single-centre experience. Transplant Proc. 2005;37:2569-2570.
3. Saab S, Ghobrial RM, Ibrahim AB, et al. Hepatitis C positive grafts may be used in orthotopic liver transplantation: a matched analysis. Am J Transplant. 2003;3:1167-1172.
4. Northup PG, Argo CK, Nguyen DT, et al. Liver allografts from hepatitis C positive donors can offer good outcomes in hepatitis C positive recipients: a US National Transplant Registry analysis. Transpl Int. 2010;23: 1038-1044.
5. CurryMP, Forns X, Chung RT, et al. Sofosbuvir and ribavirin prevent recurrence ofHCV infection after liver transplantation: an open-label study. Gastroenterology. 2015;148:100-107. e1.
6. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
7. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
8. Taga Scott A, Washington MK, Terrault N, et al. Cholestatic hepatitis C in liver allografts. Liver Transpl Surg. 1998;4:304-310.
9. Narang TK, AhrensW, Russo MW. Post-liver transplant cholestatic hepatitisC: a systematic reviewof clinical and pathological findings and application of consensus criteria. Liver Transpl. 2010;16:1228-1235.
10. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896.
11. Bruno S, Di Marco V, Iavarone M, et al. Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. J Hepatol. 2016;64:1217-1223.
12. Mandorfer M, Kozbial K, Schwabl P, et al. Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol. 2016;27.
13. Charlton M, Gane E, Manns MP, et al. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. Gastroenterology. 2015;148:108-117.
14. KimWR, Smith JM, Skeans MA, et al. OPTN/SRTR 2012 annual data report: liver. Am J Transplant. 2014;14(S1):69-96.
15. Montenovo MI, Dick AAS, Hansen RN. Donor hepatitis C sero-status does not impact survival in liver transplantation. Ann Transplant. 2015; 20:44-50.
16. Longworth L, Bryan S. An empirical comparison of EQ-5D and SF-6D in liver transplant patients. Health Econ. 2003;12:1061-1067.
17. Ratcliffe J, Longworth L, Young T, et al. Assessing health-related quality of life pre-and post-liver transplantation: a prospective multicenter study. Liver Transpl. 2002;8:263-270.
18. Lim KC, Wang VW, Siddiqui FJ, et al. Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology. 2015;61:227-237.
19. Cortesi PA, Mantovani LG, Ciaccio A, et al. Cost-effectiveness of new direct-acting antivirals to prevent post-liver transplant recurrent hepatitis. Am J Transplant. 2015;15:1817-1826.
20. Hepatitis C Online. Sofosbuvir (Sovaldi). http://www.hepatitisc.uw.edu/page/treatment/drugs/sofosbuvir-drug#cost-and-medication-access. Updated 2016. Accessed April, 2016.
21. Hepatitis C Online. Ribavirin (Copegus, Rebetol, Ribasphere). http://www. hepatitisc.uw.edu/page/treatment/drugs/ribavirin-drug. Updated 2016. Accessed April, 2016.
22. Ledipasvir-Sofosbuvir (Harvoni)-Treatment-Hepatitis C Online [Internet]. [cited 2016 Apr 1]. Available from: http://www.hepatitisc.uw.edu/page/treatment/drugs/ledipasvir-sofosbuvir.
23. Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89-99.
24. Hagan LM, Sulkowski MS, Schinazi RF. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology. 2014;60:37-45.
25. Zhang S, Bastian ND, Griffin PM. Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US. BMC Gastroenterol. 2015;15:98.
26. Tapper EB, Catana AM, Sethi N, et al. Direct costs of care for hepatocellular carcinoma in patients with hepatitis C cirrhosis. Cancer. 2016;122: 852-858.
27. Rein DB, Borton J, Liffmann DK, et al. The burden of hepatitis C to the United States Medicare system in 2009: descriptive and economic characteristics. Hepatology. 2016;63:1135-1144.
28. Njei B, McCarty TR, Fortune BE, et al. Optimal timing for hepatitis C therapy in US patients eligible for liver transplantation: a cost-effectiveness analysis. Aliment Pharmacol Ther. 2016;44:1090-1101.
29. Vitale A, Spolverato G, Burra P, et al. Cost-effectiveness of pretransplant sofosbuvir for preventing recurrent hepatitis C virus infection after liver transplantation. Transpl Int. 2015;28:1055-1065.
30. Salazar J, Roberts J,Mehta N, et al. Relative distribution of livers fromHCV + donors in the U.S. Am J Transplant. 2016;16(suppl 3).
31. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-the curious resilience of the 50,000-per-QALY threshold. N Engl JMed. 2014;371:796-797.
32. Prenner S, VanWagner L, Kulik L. Hepatocellular carcinoma decreases chance of successful HCV therapy in the current era. Am J Transplant. 2016;16(suppl 3).
33. Verna E, Levitsky J, O'Leary J, et al. Short duration perioperative administration of ledipasvir/sofosbuvir is safe and effective in preventing HCV recurrence after liver transplant. Am J Transplant. 2016;16(suppl 3).